Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
20 May 2024
|
|
23:07 | User:Rithish Nimmagadda 3 changes history +62 [Rithish Nimmagadda (3×)] | |||
|
|
23:07 (cur | prev) +25 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
20:32 (cur | prev) +23 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
20:18 (cur | prev) +14 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 23:07 | Velmanase alfa-tycv diffhist +7,709 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=velmanase alfa-tycv |aOrAn=an |drugClass=recombinant preparation of human lysosomal alpha-mannosidase |indicationType=treatment |indication=non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients |adverseReactions=Most common adverse reactions (incidence >20%) are hypersensitivity reactions (including anaphylaxis), nasopharyngitis, pyrexia, headache, and arthralgia. |blac...") | ||||
|
|
N 20:36 | Retifanlimab-dlwr 3 changes history +8,754 [Rithish Nimmagadda (3×)] | |||
|
|
20:36 (cur | prev) −296 Rithish Nimmagadda talk contribs | ||||
|
|
20:33 (cur | prev) +86 Rithish Nimmagadda talk contribs | ||||
| N |
|
20:31 (cur | prev) +8,964 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=retifanlimab-dlwr |aOrAn=an |indicationType=treatment |indication=adults with metastatic or recurrent locally advanced Merkel cell carcinoma . Indication approved under accelerated approval based on tumor response rate and duration of response; continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. |adverseReactions=Adverse effects (≥10%): fatigue...") | |||
| N 20:18 | Tofersen diffhist +3,936 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=tofersen |aOrAn=an |drugClass=antisense oligonucleotide |indicationType=treatment |indication=amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. |adverseReactions=he most common adverse reactions (≥ 10% of patients treated with tofersen and greater than placebo) were pain, fatigue, arthralgia, increased CSF white blood cell, and myalgia. |fdaLIADAdult=...") | ||||
| m 19:55 | Non-degenerate nucleotides per response element diffhist −51 Marshallsumter talk contribs (→Tabulation of counts) | ||||
|
|
03:56 | Leniolisib 2 changes history +3,116 [Alen Antony (2×)] | |||
|
|
03:56 (cur | prev) +1,712 Alen Antony talk contribs | ||||
|
|
03:38 (cur | prev) +1,404 Alen Antony talk contribs | ||||
19 May 2024
| 21:29 | Industrial and organizational psychology diffhist +282 Badgettrg talk contribs (→Engagement) | ||||
| m 08:44 | Non-degenerate nucleotides per response element diffhist −58 Marshallsumter talk contribs (→Tabulation of counts) | ||||
| 03:54 | Chronic obstructive pulmonary disease history and symptoms diffhist +1,728 Kosar Doraghi talk contribs | ||||
18 May 2024
| 16:02 | User:Rithish Nimmagadda diffhist +18 Rithish Nimmagadda talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
N 16:02 | Ritlecitinib 2 changes history +10,128 [Rithish Nimmagadda (2×)] | |||
|
|
16:02 (cur | prev) +22 Rithish Nimmagadda talk contribs | ||||
| N |
|
16:01 (cur | prev) +10,106 Rithish Nimmagadda talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{VSRN}} |genericName=ritlecitinib |aOrAn=a |drugClass=janus kinase 3 (JAK3) inhibitor and also an inhibitor of the tyrosine kinase |indicationType=treatment |indication=severe alopecia areata in adults and adolescents 12 years of age and older |hasBlackBoxWarning=Yes |adverseReactions=Most common adverse reactions (incidence ≥1%) are headache, diarrhea, acne, rash, urticaria, folliculitis, pyrexia, atopic dermatitis, dizziness, i...") | |||
|
|
00:29 | User:Archana.vajjala 2 changes history 0 [Archana.vajjala (2×)] | |||
|
|
00:29 (cur | prev) −6 Archana.vajjala talk contribs (→Dr Archana Yadav Vajjala) Tags: Manual revert Visual edit | ||||
|
|
00:23 (cur | prev) +6 Archana.vajjala talk contribs Tags: Manual revert Visual edit | ||||